- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02385318
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
29 oktober 2021 uppdaterad av: Padagis LLC
The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
519
Fas
- Fas 3
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria
- Provide written informed consent/assent
- Healthy male or non-pregnant females, >18 years old
- Subjects must have clinical diagnosis of actinic keratosis
- Subjects must be in general good health and free from any clinically significant disease that might interfere with the study evaluations in the opinion of the investigator
- Subjects must be willing to refrain from using non-approved products on the targeted treatment area during the study period.
- Subjects should be willing to refrain from using any type of bandage or dressing on the treatment area or apply the gel to open skin wounds, infections, or exfoliative dermatitis.
- Subjects must be willing and able to comply with the requirements of the study for the duration of the study period.
- Females of childbearing potential willing to use an acceptable form of birth control
Exclusion
- Females who are pregnant, nursing, or planning a pregnancy within the study participation period
- Subjects who are immunocompromised or HIV positive or who have any immune-system disorders including auto-immune disease
- Subjects who have or had an active herpes infection within 14 days prior to the baseline visit
- Subjects who have any evidence of carcinoma or any other cancer on the face and scalp
- Presence of an incompletely healed wound within the treatment area or within 5cm of the treatment area
- Presence of any skin condition in the treatment area that may be made worse by treatment with the study medication
- Subjects who have used a tanning salon, tanning booth, sunbathing or have excessive prolonged exposure to the sun 7 days prior to Visit 1/Day 1 (baseline) or planned throughout the study
- Subjects who plan to use artificial tanners within 5cm of the selected treatment area throughout the study
- Use of NSAIDs within 7 days from Visit 1/Day 1 (Baseline) or initiation during the trial.
- Subjects who had select cosmetic or therapeutic procedures within 2cm of the selected treatment area and within 14 days of Visit 1/Day 1 (baseline) or within 10cm of the selected treatment area planned anytime during the study.
- Subjects who have had or are scheduling elective surgery within 1 month before or after the study period
- Prior use within 30 days of Visit 1/ Day 1 (baseline) or planned use during the study of immunomodulators, immunosuppressive therapies, interferon, interferon inducers, systemic corticosteroids, and cytotoxic drugs
- Subjects undergoing treatment or received treatment within 8 weeks of Visit 1/Day 1 (baseline) and within 2cm of the selected area or planned during anytime in the study of: 5-FU, imiquimod, diclofenac, photodynamic therapy used in combination with photosensitizing cream.
- Subjects who used PUVA or UVB therapy on the face or scalp within 6 months prior to Visit 1/Day 1 (baseline) or are planning to receive PUVA therapy, UVB therapy, or nonprescription UV light sources anywhere on the body during the study.
- Subjects who have taken systemic chemotherapy medications within the last 6 months prior to Visit 1/Day 1 (baseline) or planned use anytime during the study.
- Subjects who have undergone resurfacing procedures within the last 6 months prior to Visit 1/Day 1 (baseline) or planned use anytime during the study.
- Subjects who have been treated within 1 month or planning to receive treatment with systemic retinoids, hyaluronic acid, other medicated actinic keratosis therapy, or topical steroids anywhere on the head during the study.
- Subject who have a history of hypersensitivity or allergy to any ingredient in the drug product.
- Use of medicated make-up in the treatment area or significant change in the use of consumer products within 30 days of Visit 1/Day 1 (baseline) and planned use or change throughout the study.
- Start or change of dose of hormonal treatment within the past 3 months (90 days) or planned start/change throughout the study.
- Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements
- Participation in any clinical study involving an investigational product, agent, or device in the 30 days prior to Visit 1/Day 1 (baseline) or throughout the study
- Subjects who have been previously enrolled in this study
- Employee of the research center or private practice
- Subjects who in the opinion of the investigator are unlikely to be able to follow the restrictions of the protocol and complete the study
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placeboprodukt
Placebo gel
|
|
Experimentell: Test Product
Ingenol Mebutate
|
Andra namn:
|
Aktiv komparator: Reference product
Ingenol Mebutate
|
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator
Tidsram: Day 57
|
Day 57
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 februari 2015
Primärt slutförande (Faktisk)
1 december 2015
Avslutad studie (Faktisk)
1 december 2015
Studieregistreringsdatum
Först inskickad
30 januari 2015
Först inskickad som uppfyllde QC-kriterierna
5 mars 2015
Första postat (Uppskatta)
11 mars 2015
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
2 november 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 oktober 2021
Senast verifierad
1 oktober 2021
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PRG-NY-14-019
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Aktinisk keratos
-
Premier Specialists, AustraliaThe University of New South WalesAktiv, inte rekryterandeKeratosis PilarisAustralien
-
University of California, DavisAvslutadKeratosis, ActinicFörenta staterna
-
Graceway Pharmaceuticals, LLCAvslutad
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, France; National...AvslutadKeratosis, ActinicFrankrike
-
DUSA Pharmaceuticals, Inc.AvslutadKeratosis, ActinicFörenta staterna
-
Almirall, S.A.Har inte rekryterat ännu
-
Blackwell Device ConsultingEmblation LimitedRekrytering
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, France; European...AvslutadKeratosis, ActinicFrankrike, Tyskland
-
Maastricht University Medical CenterOkändKeratosis, ActinicNederländerna
Kliniska prövningar på Placebo gel
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... och andra samarbetspartnersAvslutadFriskaFörenta staterna, Puerto Rico
-
Topokine Therapeutics, Inc.UpphängdÖverskott av submentalt fett ("Double Chin")
-
Population CouncilAvslutadHIV-infektionFörenta staterna
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Rekrytering
-
Starpharma Pty LtdAvslutadÅterkommande bakteriell vaginos (BV)
-
Suzhou Kintor Pharmaceutical Inc,AvslutadAcne vulgaris | Androgen alopeciFörenta staterna
-
Kalypsys, Inc.AvslutadNeuropatisk smärta | Bältros | Postherpetisk neuralgi | BältrosFörenta staterna
-
Starpharma Pty LtdAvslutadBakteriell vaginosFörenta staterna
-
Xinnate ABRegion SkaneAvslutadBlåsa | Epidermolysis Bullosa | Hudens sår | Åderbråck sår i nedre extremiteterSverige
-
Università degli Studi dell'InsubriaOkänd